Literature DB >> 10460662

p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome.

R M Feakins1, H E Mulcahy, C D Nickols, C A Wells.   

Abstract

AIMS: To study p53 protein expression in phyllodes tumours of the breast, with particular attention to its prevalence and to its relationship with histological features and clinical outcome. METHODS AND
RESULTS: Stromal and epithelial p53 immunohistochemical expression was studied in 57 phyllodes tumours (27 benign, 17 borderline, 13 malignant) using an avidin-biotin peroxidase method. High levels of expression (> 30% of stromal nuclei) were found in eight phyllodes tumours (14%). p53 expression was associated with tumour grade (P = 0.001), prominent stromal overgrowth (P = 0.0003), prominent stromal nuclear pleomorphism (P = 0.006), high stromal mitotic count (P = 0.05), and an infiltrative tumour margin (P = 0. 05). Six patients were lost to follow-up after surgery. Mean follow-up time of the remaining 51 patients was 7.3 years (median 4. 3, range 0.5-25) or until death. Sixteen patients (31%) experienced tumour recurrence. Recurrence was more likely if there was an infiltrative tumour margin (P = 0.006) or prominent stromal overgrowth (P = 0.04) but not p53 expression (P = 0.55). A minority of recurrences expressed p53 more extensively than their primary counterparts. There were five tumour-related deaths (10% of patients). Death was associated with high grade (P = 0.0002), prominent stromal overgrowth (P = 0.0001), an infiltrative margin (P = 0.0002), prominent nuclear pleomorphism (P = 0.005), a high mitotic count (P = 0.01) and tumour size (P = 0.03). Again, p53 expression was not associated with tumour-related survival (P = 0. 13).
CONCLUSIONS: p53 abnormalities occur in a minority of borderline and malignant phyllodes tumours. p53 expression is associated with known negative prognostic factors, but does not appear to be a useful determinant of tumour recurrence or long-term survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460662     DOI: 10.1046/j.1365-2559.1999.00682.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Genomic landscapes of breast fibroepithelial tumors.

Authors:  Jing Tan; Choon Kiat Ong; Weng Khong Lim; Cedric Chuan Young Ng; Aye Aye Thike; Ley Moy Ng; Vikneswari Rajasegaran; Swe Swe Myint; Sanjanaa Nagarajan; Saranya Thangaraju; Sucharita Dey; Nur Diyana Md Nasir; Giovani Claresta Wijaya; Jing Quan Lim; Dachuan Huang; Zhimei Li; Bernice Huimin Wong; Jason Yong Sheng Chan; John R McPherson; Ioana Cutcutache; Gregory Poore; Su Ting Tay; Wai Jin Tan; Thomas Choudary Putti; Buhari Shaik Ahmad; Philip Iau; Ching Wan Chan; Anthony P H Tang; Wei Sean Yong; Preetha Madhukumar; Gay Hui Ho; Veronique Kiak Mien Tan; Chow Yin Wong; Mikael Hartman; Kong Wee Ong; Benita K T Tan; Steven G Rozen; Patrick Tan; Puay Hoon Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

Review 2.  Phyllodes tumours.

Authors:  S J Parker; S A Harries
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

3.  Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.

Authors:  Gary M Tse; Benjaporn Chaiwun; Kin-Mang Lau; Richard Scolyer; C Soon Lee; Rooshdiya Z Karim; Thomas C Putti; Bonita K Law; Philip C Lui; Puay Hoon Tan
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

Review 4.  A very large malignant phyllodes tumor with skin ulceration and nipple areola complex involvement-still a reality!!!

Authors:  Shwetank Prakash; Prince Raj
Journal:  Indian J Surg       Date:  2012-04-18       Impact factor: 0.656

Review 5.  Optimising preoperative diagnosis in phyllodes tumour of the breast.

Authors:  R K Jacklin; P F Ridgway; P Ziprin; V Healy; D Hadjiminas; A Darzi
Journal:  J Clin Pathol       Date:  2006-02-06       Impact factor: 3.411

6.  Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.

Authors:  Su-Yang Liu; Nancy M Joseph; Ajay Ravindranathan; Bradley A Stohr; Nancy Y Greenland; Poonam Vohra; Elizabeth Hosfield; Iwei Yeh; Eric Talevich; Courtney Onodera; Jessica A Van Ziffle; James P Grenert; Boris C Bastian; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

7.  Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.

Authors:  Zoran Gatalica; Semir Vranic; Anatole Ghazalpour; Joanne Xiu; Idris Tolgay Ocal; John McGill; Ryan P Bender; Erin Discianno; Aaron Schlum; Souzan Sanati; Juan Palazzo; Sandeep Reddy; Barbara Pockaj
Journal:  Oncotarget       Date:  2016-01-12

8.  A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.

Authors:  Yirong Sim; Gwendolene Xin Pei Ng; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Suet Far Wong; Wei Liu; Peiyong Guan; Sanjanaa Nagarajan; Wai Yee Ng; Aye Aye Thike; Jeffrey Chun Tatt Lim; Nur Diyana Binte Md Nasir; Veronique Kiak Mien Tan; Preetha Madhukumar; Wei Sean Yong; Chow Yin Wong; Benita Kiat Tee Tan; Kong Wee Ong; Bin Tean Teh; Puay Hoon Tan
Journal:  BMC Med Genomics       Date:  2019-10-23       Impact factor: 3.063

9.  Phyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis.

Authors:  Samer Sawalhi; Marwa Al-Shatti
Journal:  Ann Saudi Med       Date:  2013 Mar-Apr       Impact factor: 1.526

10.  P53 Expression in benign Breast Disease Development: A Systematic Review.

Authors:  Rafaela Soares Senra da Costa; Ilce Ferreira Da Silva
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.